Decision spine
Frames the controlling thesis, evidence status, buyer implications, and research-use limits.
Infectious Disease
Zemi Dossier
Research-use only
Invasive Fungal Disease & Antifungal Resistance
A decision package on the antifungal scarcity stack: diagnosis, species coverage, resistance, host vulnerability, toxicity, and clinical-development feasibility.
Decision this dossier helps answer
Which antifungal or diagnostic programs address the binding scarcity layer, and what evidence would change countermeasure priority?
Problem this dossier solves
The constraint is a stacked scarcity problem.
The dossier treats invasive fungal disease as a chain of shortages: fast diagnosis, safe drugs, resistant-species coverage, validated endpoints, and deployable host-risk logic. The decision value is knowing which shortage actually controls the next move.
What is moving: current field evidence and platform activity
What is unresolved: decision-grade proof, endpoint logic, and failure modes
What Zemi solves: evidence-gated next-study strategy
Full decision package
109-page research report plus 44-sheet Evidence & Decision Workbook
Buy now
$3,500$5,500Launch price
Controlling thesis
The constraint is a stacked scarcity problem.
The dossier treats invasive fungal disease as a chain of shortages: fast diagnosis, safe drugs, resistant-species coverage, validated endpoints, and deployable host-risk logic. The decision value is knowing which shortage actually controls the next move.
A Zemi Dossier turns uncertain emerging research into a decision package: what is known, what is inferred, what is hypothetical, what would falsify the thesis, and what should be built, funded, avoided, monitored, or validated next.
Research report preview
First 30 pages of the actual Invasive Fungal Disease & Antifungal Resistance research report.
The public page shows the real document style, density, evidence posture, and decision framing before a buyer requests access to the full Zemi Dossier package.
Research report
The research report is the argument. It is not the whole product.
The PDF research report is the structured argument: field status, evidence maturity, buyer implications, falsifiable hypotheses, power-calculated next studies, strategic recommendations, limitations, and traceability posture.
Inspectable infrastructure
Pairs the report with claim ledgers, evidence tables, power rows, audit surfaces, and decision tools.
Executable next studies
Links hypotheses to endpoint logic, assumptions, sample-size logic, budget, and timeline planning.
Research report table of contents
Public TOC generated from the source report.
The full research report is delivered as a licensed PDF. This table shows the decision structure without publishing the full product.
| Section | What it covers | Buyer value |
|---|---|---|
| Executive Summary | Condenses the dossier thesis, evidence posture, buyer implications, and next-study priorities. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Decision Brief Read This First | Turns the report into immediate buyer triage: what matters now, what is still uncertain, and what to do next. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Scope and Evidence Integrity | Defines the evidence window, source boundaries, research-use limits, and labeling discipline. | Lets the buyer audit support strength before relying on the package. |
| Decision Snapshot Overview | Maps findings to buyer actions: build, fund, avoid, monitor, or validate next. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| How to read the snapshot | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Buyer Decision Cheat Sheet | Maps findings to buyer actions: build, fund, avoid, monitor, or validate next. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Using the cheat sheet without misusing it | Maps findings to buyer actions: build, fund, avoid, monitor, or validate next. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Source Quality Dashboard | Shows how strong the source base is and where conclusions depend on indirect or thinner support. | Lets the buyer audit support strength before relying on the package. |
| The grading philosophy, made explicit | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Antifungal Scarcity Stack Model | Defines the governing argument and the evidence gates that would support or falsify it. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| The law | Defines the governing argument and the evidence gates that would support or falsify it. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Layer 1 - Target scarcity (the eukaryotic ceiling) | Defines the governing argument and the evidence gates that would support or falsify it. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Layer 2 - Detection scarcity (the diagnostic abyss) | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Layer 3 - Resistance pre-loading (the poisoned well / One Health) | Explains which biological signals matter for interpreting the field and discriminating between programs. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| The meta-layer - Evidentiary translation | Shows how strong the source base is and where conclusions depend on indirect or thinner support. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| The new-target premium and its disciplining caveat | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| The flagship architecture the model implies | Defines the governing argument and the evidence gates that would support or falsify it. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Delivery Scarcity Corollary | Identifies translational, regulatory, safety, or delivery constraints that shape whether the thesis can be tested. | Shows where the thesis could fail or require more validation before action. |
| Scarcity Stack Classifier | Operationalizes the thesis as a reusable decision surface for comparing programs or evidence states. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| Current Signal Update 2025 2026 | Frames the field's June 2026 state, active programs, research fronts, and timing signals. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| The novel-mechanism pipeline matured - unevenly | Explains which biological signals matter for interpreting the field and discriminating between programs. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| The resistance side accelerated | Explains which biological signals matter for interpreting the field and discriminating between programs. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Standards and funding moved too | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Reading the 2025-2026 inflection through the Stack | Frames the field's June 2026 state, active programs, research fronts, and timing signals. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| The catalysts to watch, dated | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Current Signal Refresh | Frames the field's June 2026 state, active programs, research fronts, and timing signals. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Named Discoveries | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Cross Constraint Convergence Map | Shows how separate research signals converge, diverge, or interact across domains, mechanisms, or study layers. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Coupling 1 - Target scarcity x cross-resistance: a new target outvalues potency, and pan-class cross-resistance is the real catastrophe | Shows how separate research signals converge, diverge, or interact across domains, mechanisms, or study layers. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Coupling 2 - Detection clock x empirical lock-in x mortality | Shows how separate research signals converge, diverge, or interact across domains, mechanisms, or study layers. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Coupling 3 - Agricultural azole x clinical failure: source-control is a farm problem | Shows how separate research signals converge, diverge, or interact across domains, mechanisms, or study layers. | Lets the buyer audit support strength before relying on the package. |
| Coupling 4 - The new target is a new well you are already poisoning (resistance pre-loading x target scarcity) | Shows how separate research signals converge, diverge, or interact across domains, mechanisms, or study layers. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Coupling 5 - Deploy-first-line versus reserve-as-salvage: the new-target durability dilemma | Shows how separate research signals converge, diverge, or interact across domains, mechanisms, or study layers. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Coupling 6 - Host immunity x drug efficacy: sometimes the binding constraint is the patient, not the fungus | Shows how separate research signals converge, diverge, or interact across domains, mechanisms, or study layers. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Coupling 7 - Thermotolerance x emergence and CLSI-versus-EUCAST discordance: two cheap, high-leverage edges | Shows how separate research signals converge, diverge, or interact across domains, mechanisms, or study layers. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Coupling 8 - Delivery scarcity x resistance scarcity: the safest target is the hardest to deploy | Shows how separate research signals converge, diverge, or interact across domains, mechanisms, or study layers. | Shows where the thesis could fail or require more validation before action. |
Evidence & Decision Workbook
The workbook is the decision engine.
A locked public preview of selected workbook-derived sheets: sheet structure, decision modules, power rows, traceability, and audit posture. Licensed buyers receive the full workbook files.
Read-only workbook preview with clipped values and no formulas. Licensed buyers receive the full Evidence & Decision Workbook with editable assumptions and working files.
Workbook inventory
Delivered workbook sheets.
Full inventories belong on dossier pages, not the homepage. Sheet names below are extracted from the actual workbook file.
| # | Workbook sheet | What it does |
|---|---|---|
| 1 | Workbook Guide | Navigation layer for using the workbook, understanding sheet roles, and following the decision package. Public preview exposes Source run, FAILED-gate task:da58235b8564d48b. fields and clipped entries such as Verification date, June 2026 cut; independent.,. |
| 2 | Claim Ledger | Claim-by-claim ledger showing verdicts, source support, inference status, and decision relevance. Public preview exposes claim_id, report_page/section, claim_text, primary_citation fields and clipped entries such as K001, report §Clinical & Translational. |
| 3 | Evidence Table | Evidence-verification surface for checking sources, support quality, and the audit trail. Public preview exposes identifier, title, journal, year fields and clipped entries such as NCT:NCT03583164, Phase IIb Study of F901318 as., ClinicalTrials.gov —. |
| 4 | Source-Support Verdicts | Independent check on whether key claims are actually supported by cited sources. Public preview exposes claim_id, primary_citation, verdict, verbatim_excerpt (verified) fields and clipped entries such as K001, NCT:NCT03583164, SUPPORTS_EXACTLY. |
| 5 | Source Quality Summary | Summary of source strength, gaps, and areas where conclusions depend on weaker evidence. Public preview exposes Evidence directness / maturity., Direct, 2 fields and clipped entries such as Adjacent, Inferential. |
| 6 | Antifungal Class Scorecard | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes agent/class, target novelty, cross-resistance exposure, evidence maturity fields and clipped entries such as Azoles (Cyp51), Existing, Catastrophic. |
| 7 | Constraint-Layer Scorecard | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes layer, binding mechanism, highest-leverage lever, evidence coverage (claims) fields and clipped entries such as Layer 1 — Target scarcity, ~4. |
| 8 | Pathogen Strategy Tracker | Tracks programs, trials, sponsors, or competitive context for diligence and monitoring. Public preview exposes pathogen, WHO FPPL tier, dominant resistance, favourable countermeasure (this. fields and clipped entries such as Aspergillus fumigatus (azole-R),. |
| 9 | Asset-Sponsor Tracker | Tracks programs, trials, sponsors, or competitive context for diligence and monitoring. Public preview exposes asset, sponsor, modality/target, stage / regulatory fields and clipped entries such as Olorofim, F2G Biotech, DHODH inhibitor (orthotomide). |
| 10 | Trial-Catalyst Tracker | Tracks programs, trials, sponsors, or competitive context for diligence and monitoring. Public preview exposes NCT, title, status, phase fields and clipped entries such as NCT02956499, A First-in-Human, Randomized,., COMPLETED. |
| 11 | Resistance-Mechanism Tracker | Tracks programs, trials, sponsors, or competitive context for diligence and monitoring. Public preview exposes mechanism, affected class, pathogen(s), driver / note fields and clipped entries such as Cyp51A TR34/L98H, Azole, A. fumigatus. |
| 12 | Diagnostic Performance Tracker | Tracks programs, trials, sponsors, or competitive context for diligence and monitoring. Public preview exposes assay, target, performance, turnaround fields and clipped entries such as Blood culture, Invasive candidiasis, ~40% sensitivity. |
| 13 | One-Health Surveillance Tracker | Tracks programs, trials, sponsors, or competitive context for diligence and monitoring. Public preview exposes driver/reservoir, resistance signature, compartment, finding fields and clipped entries such as Agricultural azole (DMI) fungicides, TR34/L98H,. |
| 14 | Biomarker-Endpoint Map | Tracks biomarkers or readouts that determine whether the thesis is moving toward testable evidence. Public preview exposes biomarker/endpoint, role, status/definition, note fields and clipped entries such as Beta-D-glucan, Rule-out / stop-decision support,. |
| 15 | Regulatory Tracker | Tracks regulatory, endpoint, reimbursement, or qualification requirements that shape testing strategy. Public preview exposes agent, sponsor, channel & status, summary fields and clipped entries such as Olorofim, F2G, Breakthrough Therapy + Orphan + QIDP.. |
| 16 | Figure Source Map | Traceability surface linking claims, figures, calculations, and workbook outputs back to sources. Public preview exposes figure_id, caption, section anchor, family fields and clipped entries such as fig01_grade_recalibration, Source-quality dashboard for the. |
| 17 | Figure Attempt Ledger | Figure and numeric reproduction log for validating calculations, chart inputs, or displayed values. Public preview exposes figure_id, family, data_type, grade fields and clipped entries such as fig01_grade_recalibration, evidence_grade_distribution,. |
| 18 | Hypotheses Ledger | Maps hypotheses to evidence state, falsification logic, endpoints, and next-study design. Public preview exposes id, tier, paradigm, axis (layers/pathogens coupled) fields and clipped entries such as F1, Flagship, The Scarcity-Stack pragmatic trial -.. |
| 19 | Most Valuable Next Studies | Prioritizes next studies that could change the decision, including endpoints and evidence gates. Public preview exposes id, study, primary endpoint, failure criterion fields and clipped entries such as S1 (flagship), Diagnostic-guided,., All-cause mortality. |
| 20 | Verification & Search Log | Release-discipline surface for revisions, unresolved issues, audit findings, and readiness tracking. Public preview exposes database, query, hits fields and clipped entries such as SUMMARY, 192 identifiers re-verified (105., pubmed. |
| 21 | Excluded Claims | Disposition log for rejected, bounded, or quarantined claims so they do not leak into the decision thesis. Public preview exposes claim_id, exclusion set, claim (truncated), citation fields and clipped entries such as O001, O, Therapeutic viruses (phage,.. |
| 22 | Salvage Ledger | Disposition log for rejected, bounded, or quarantined claims so they do not leak into the decision thesis. Public preview exposes source element, action, what changed, evidence/anchor fields and clipped entries such as Positioning: IFD as the other half.,. |
| 23 | 23. Evidence Maturity Matrix | Evidence-verification surface for checking sources, support quality, and the audit trail. Public preview exposes agent / class, target novelty (0-4), cross-resistance escape (0-4), detection fit (0-4) fields and clipped entries such as Olorofim (DHODH), 4. |
| 24 | 24. Power Calculations | Power-calculation layer for assumptions, endpoint logic, computed sample sizes, and sensitivity checks. Public preview exposes hypothesis_id, study_id, endpoint, test_type fields and clipped entries such as F1, F1a, 30-day all-cause mortality (DOOR),.. |
| 25 | Power Sensitivity | Power-calculation layer for assumptions, endpoint logic, computed sample sizes, and sensitivity checks. Public preview exposes scenario, input 1, input 2, alpha fields and clipped entries such as effect x1.00 (design), 0.3, 0.22. |
| 26 | 25. Competitive Landscape | Tracks programs, trials, sponsors, or competitive context for diligence and monitoring. Public preview exposes Company, Asset / platform, Modality / target, Novelty class fields and clipped entries such as F2G / Shionogi, Olorofim, DHODH (orthotomide). |
| 27 | SSC_Input_Template | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Evidence completeness, 0-1: fraction of the panel., ____ fields and clipped entries such as Agricultural analogue, if pre-loading binds, enter:.,. |
| 28 | SSC_Feature_Score | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes EVIDENTIARY-TRANSLATION-BINDING, Evidentiary translation: the., 1, 1 fields from this sheet. |
| 29 | SSC_Class_Output | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Evidence completeness (ENTER 0-1), 0.8 fields and clipped entries such as Agricultural analogue (ENTER., none, Archetype (severity scores). |
| 30 | SSC_Decision_Rules | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes HOST-LIMITATION-BINDING, Host-gated: the binding., HOST-STRATIFIED - the antifungal., validated immune-status biomarker fields and clipped entries. |
| 31 | SSC_Analogue_Rules | Workbook surface supporting a specific evidence, decision, study-planning, or release-control workflow. Public preview exposes ipflufenoquin, RESERVE: a non-selective., olorofim cross-resistance., restrict agricultural. fields and clipped entries such as. |
| 32 | SSC_Minimum_Assay_Panel | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Immune-status markers (lymphocyte., Host, Preferred fields and clipped entries such as Evidence-grade audit (controlled vs., Evidentiary, Required. |
| 33 | SSC_Archetype_Cards | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Archetype, Profile (severities), Binding layer, Matched move fields and clipped entries such as Azole x azole-R A. fumigatus (TR34., target 3,. |
| 34 | SSC_Validation_Log | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Outcome endpoint, DOOR-ranked 30-day mortality /. fields and clipped entries such as Calibration, required (reliability across sites), Weights. |
| 35 | SSC_Traceability_Map | Traceability surface linking claims, figures, calculations, and workbook outputs back to sources. Public preview exposes SSC element, Maps to claim/finding, Evidence ID, Figure fields and clipped entries such as Target-scarcity layer, kf-target-scarcity;.,. |
| 36 | 33. Traceability Certificate | Traceability surface linking claims, figures, calculations, and workbook outputs back to sources. Public preview exposes claim_id, report_section, report_page, claim_text fields and clipped entries such as K001, Clinical & Translational Implications, report. |
| 37 | 34. Score Basis | Explains how scores or ratings were assigned so the decision instrument can be inspected. Public preview exposes fig05 layer coverage, claim count, number of customer-facing claims. fields and clipped entries such as fig06 target druggability, 0-4, target. |
| 38 | 35. Validation - Falsification | Connects proposed validation work to falsification criteria, readouts, and decision gates. Public preview exposes Agricultural > clinical azole., F5 / Coupling 3, One-Health source-control leverage, clinical use predicts resistance. fields and clipped. |
| 39 | 36. Quarantine Register | Disposition log for rejected, bounded, or quarantined claims so they do not leak into the decision thesis. Public preview exposes Item, Claim quarantined, Why quarantined, Disposition / label fields and clipped entries such as MAT2203 Phase 3 'met primary. |
| 40 | 37. Version Registry | Release-discipline surface for revisions, unresolved issues, audit findings, and readiness tracking. Public preview exposes v2.0 (premium), June 2026, Premium Tier C elevation of the., Claude (Opus 4.8) fields and clipped entries such as v1.0, June 2026,. |
| 41 | 38. Audit Issues Log | Release-discipline surface for revisions, unresolved issues, audit findings, and readiness tracking. Public preview exposes #, Issue, Status, Resolution fields and clipped entries such as AI-1, Workbook genuinely executable?, RESOLVED. |
| 42 | 39. Full-Text Adjudication | Workbook surface supporting a specific evidence, decision, study-planning, or release-control workflow. Public preview exposes claim_id, primary_source_id, passage_checked_status, source_access_type fields and clipped entries such as K001, NCT:NCT03583164,. |
| 43 | 40. SSC Back-Test | Workbook surface supporting a specific evidence, decision, study-planning, or release-control workflow. Public preview exposes case_id, known asset-pathogen case, known real-world status, SSC inputs fields and clipped entries such as SBT-01, Azole-resistant. |
| 44 | 41. Asset IP-Diligence | Tracks programs, trials, sponsors, or competitive context for diligence and monitoring. Public preview exposes asset/platform, sponsor / owner, patent/IP posture, partner obligations fields and clipped entries such as Olorofim, F2G / Shionogi, First-in-class. |
Power-calculated next studies
Power calculations are the execution bridge.
Power calculations are planning-grade research calculations for endpoint logic, assumptions, sample size, budget, and timeline. They do not prove hypotheses or constitute clinical protocol.
| Hypothesis | Primary endpoint | Test | Effect | α | Power | Computed n | Design n |
|---|---|---|---|---|---|---|---|
| F1 | 30-day all-cause mortality (DOOR), SSC-guided vs usual care | two-proportion | 0.3 | 0.05 | 0.80 | 471 | 500 |
| F1 | SSC held-out discrimination (AUC) vs MIC/potency baseline | AUC (Hanley-McNeil, external) | 0.8 | 0.05 | 0.80 | 26 | 200 |
| F2 | Environmental olorofim non-WT incidence: non-selective vs low agri-DH... | two-proportion | 0.08 | 0.05 | 0.80 | 206 | 260 |
| F3 | Regional fungal-active drug-years to pan-resistance: first-line vs sa... | two-sample t | 1.0 | 0.05 | 0.80 | 16 | 12 |
| F4 | Appropriate-empirical-therapy proportion: rapid species+resistance Dx... | two-proportion | 0.55 | 0.05 | 0.80 | 125 | 300 |
Release audit discipline
Audit posture is part of the product.
Public pages do not publish exact audit scores. They should state the release discipline, revision posture, and limitations without implying peer review or validated clinical guidance.
Research-use decision package
Not medical advice, clinical guidance, investment advice, or a clinical protocol.
Known / inferred / hypothetical
The package separates cited evidence from inference and frontier hypothesis generation.
Audit-gated and revision-controlled
Adversarial audit checks source support, formulas, figures, limitations, and release readiness.
Buy this dossier
Full decision package — 109-page report + 44-sheet workbook
Buy now
- Decision research report (109 pages, PDF)
- Evidence & Decision Workbook (44 sheets, .xlsx) — claims, source-support verdicts, power calculations, traceability, and audit log
- Live, editable power-calculated next studies
$3,500$5,500Launch price